Related references
Note: Only part of the references are listed.853PPREDICTION OF RESPONSE OF PRIMARY TUMORS TO NEOADJUVANT SUNITINIB USING PERFUSION (DCE) COMPUTED TOMOGRAPHY (CT) IN METASTATIC RENAL CELL CARCINOMA (MRCC) PATIENTS (PREINSUT TRIAL)
M. Bouaboula et al.
ANNALS OF ONCOLOGY (2017)
Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma
L. Zhou et al.
ONCOGENE (2016)
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
B. Escudier et al.
ANNALS OF ONCOLOGY (2016)
Phase I study of safety and tolerability of sunitinib in combination with sirolimus in patients with refractory solid malignancies and determination of VEGF (VEGF-A) and soluble VEGF-R2 (sVEGFR2) in plasma
Jia Li et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2016)
Clinical activity of sunitinib rechallenge in metastatic renal cell carcinoma-Results of the REchallenge with SUnitinib in MEtastatic RCC (RESUME) Study
Stephane Oudard et al.
EUROPEAN JOURNAL OF CANCER (2016)
Long-term Safety of Sunitinib in Metastatic Renal Cell Carcinoma
Camillo Porta et al.
EUROPEAN UROLOGY (2016)
Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial
Nizar M. Tannir et al.
EUROPEAN UROLOGY (2016)
Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study
David F. McDermott et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial
Naomi B. Haas et al.
LANCET (2016)
Everolimus versus sunitinib for patients with metastatic non-clear-cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial
Andrew J. Armstrong et al.
LANCET ONCOLOGY (2016)
Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy
A. Ravaud et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma
Jeffrey J. Wallin et al.
NATURE COMMUNICATIONS (2016)
Long-term use of sunitinib in metastatic renal cell carcinoma: no unpleasant surprises about tolerability
Constance Michel et al.
TRANSLATIONAL CANCER RESEARCH (2016)
Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis
S. Bracarda et al.
ANNALS OF ONCOLOGY (2015)
RandomizEd phase II trial of Sunitinib four weeks on and two weeks off versus Two weeks on and One week off in metastatic clear-cell type REnal cell carcinoma: RESTORE trial
J. L. Lee et al.
ANNALS OF ONCOLOGY (2015)
First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: a phase II study (SUPAP) by the French Genitourinary Group (GETUG)
A. Ravaud et al.
ANNALS OF ONCOLOGY (2015)
Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients
Frede Donskov et al.
BRITISH JOURNAL OF CANCER (2015)
Phase 2 Trial of Sunitinib and Gemcitabine in Patients With Sarcomatoid and/or Poor-Risk Metastatic Renal Cell Carcinoma
M. Dror Michaelson et al.
CANCER (2015)
Orchestration and Prognostic Significance of Immune Checkpoints in the Microenvironment of Primary and Metastatic Renal Cell Cancer
Nicolas A. Giraldo et al.
CLINICAL CANCER RESEARCH (2015)
Molecular Subtypes of Clear Cell Renal Cell Carcinoma Are Associated with Sunitinib Response in the Metastatic Setting
Benoit Beuselinck et al.
CLINICAL CANCER RESEARCH (2015)
Predictive biomarkers in metastatic Renal Cell Carcinoma (mRCC) patients treated with neoadjuvant sunitinib (PREINSUT trial)
L. Mauge et al.
EUROPEAN JOURNAL OF CANCER (2015)
Sorafenib-Sunitinib Sequence: The Jury Is Out
Laurence Albiges et al.
EUROPEAN UROLOGY (2015)
SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer
Christian Eichelberg et al.
EUROPEAN UROLOGY (2015)
First-line treatment in the management of advanced renal cell carcinoma: systematic review and network meta-analysis
James Larkin et al.
EXPERT OPINION ON PHARMACOTHERAPY (2015)
Trebananib (AMG 386) in Combination With Sunitinib in Patients With Metastatic Renal Cell Cancer: An Open-Label, Multicenter, Phase II Study
Michael B. Atkins et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial
Robert J. Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab
David F. McDermott et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors
Thibault Voron et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2015)
Correlation of PD-L1 Tumor Expression and Treatment Outcomes in Patients with Renal Cell Carcinoma Receiving Sunitinib or Pazopanib: Results from COMPARZ, a Randomized Controlled Trial
Toni K. Choueiri et al.
CLINICAL CANCER RESEARCH (2015)
A phase I/II study of lenalidomide in combination with sunitinib in patients with advanced or metastatic renal cell carcinoma
B. Rini et al.
ANNALS OF ONCOLOGY (2014)
Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma
Robert J. Motzer et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2014)
A Phase I, Open-Label Study of Trebananib Combined With Sorafenib or Sunitinib in Patients With Advanced Renal Cell Carcinoma
David S. Hong et al.
CLINICAL GENITOURINARY CANCER (2014)
A 2 weeks on and 1 week off schedule of sunitinib is associated with decreased toxicity in metastatic renal cell carcinoma
Y. G. Najjar et al.
EUROPEAN JOURNAL OF CANCER (2014)
Prognostic factors in patients with advanced renal cell carcinoma treated with VEGF-targeted agents
Yann-Alexandre Vano et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2014)
Phase II Randomized Trial Comparing Sequential First-Line Everolimus and Second-Line Sunitinib Versus First-Line Sunitinib and Second-Line Everolimus in Patients With Metastatic Renal Cell Carcinoma
Robert J. Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Randomized, Controlled, Double-Blind, Cross-Over Trial Assessing Treatment Preference for Pazopanib Versus Sunitinib in Patients With Metastatic Renal Cell Carcinoma: PISCES Study
Bernard Escudier et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Clinical Outcomes for Patients with Metastatic Renal Cell Carcinoma Treated with Alternative Sunitinib Schedules
Bradley J. Atkinson et al.
JOURNAL OF UROLOGY (2014)
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Roy S. Herbst et al.
NATURE (2014)
Outcomes in patients with metastatic renal cell cancer treated with individualized sunitinib therapy: Correlation with dynamic microbubble ultrasound data and review of the literature
Georg A. Bjarnason et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2014)
Single-nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinib
B. Beuselinck et al.
BRITISH JOURNAL OF CANCER (2013)
Sunitinib adverse events in metastatic renal cell carcinoma: a meta-analysis
Ezzeldin M. Ibrahim et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2013)
Biweekly sunitinib regimen reduces toxicity and retains efficacy in metastatic renal cell carcinoma: A single-center experience with 31 patients
Bruno Neri et al.
INTERNATIONAL JOURNAL OF UROLOGY (2013)
Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Dose Escalation and Pharmacokinetics Study of Enzastaurin and Sunitinib Versus Placebo and Sunitinib in Patients With Metastatic Renal Cell Carcinoma
Manuela Schmidinger et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2012)
Multicenter phase II study of sunitinib in patients with non-clear cell renal cell carcinoma
J. -L. Lee et al.
ANNALS OF ONCOLOGY (2012)
Phase 1 Trial of Everolimus Plus Sunitinib in Patients With Metastatic Renal Cell Carcinoma
Ana M. Molina et al.
CANCER (2012)
Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma
Carlos H. Barrios et al.
CANCER (2012)
Sequential therapy with targeted agents in patients with advanced renal cell carcinoma: Optimizing patient benefit
Stephane Oudard et al.
CANCER TREATMENT REVIEWS (2012)
A Phase 2 Trial of Sunitinib in Patients with Advanced Non-clear Cell Renal Cell Carcinoma
Nizar M. Tannir et al.
EUROPEAN UROLOGY (2012)
Neoadjuvant treatment in advanced renal cell carcinoma: current situation and future perspectives
Marc-Olivier Timsit et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2012)
A phase II study of 2-methoxyestradiol nanocrystal colloidal dispersion alone and in combination with sunitinib malate in patients with metastatic renal cell carcinoma progressing on sunitinib malate
Justine Yang Bruce et al.
INVESTIGATIONAL NEW DRUGS (2012)
Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinoma
Ana M. Molina et al.
INVESTIGATIONAL NEW DRUGS (2012)
Randomized Phase II Trial of Sunitinib on an Intermittent Versus Continuous Dosing Schedule As First-Line Therapy for Advanced Renal Cell Carcinoma
Robert J. Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
The Effect of Sunitinib on Primary Renal Cell Carcinoma and Facilitation of Subsequent Surgery
Brian I. Rini et al.
JOURNAL OF UROLOGY (2012)
A Phase I study of recombinant human interleukin-21 (rIL-21) in combination with sunitinib in patients with metastatic renal cell carcinoma (RCC)
Viktor Gruenwald et al.
ACTA ONCOLOGICA (2011)
Phase 1 Dose-Escalation Trial of Tremelimumab Plus Sunitinib in Patients With Metastatic Renal Cell Carcinoma
Brian I. Rini et al.
CANCER (2011)
Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy
Eric Tartour et al.
CANCER AND METASTASIS REVIEWS (2011)
The Outcome of Patients Treated with Sunitinib Prior to Planned Nephrectomy in Metastatic Clear Cell Renal Cancer
Thomas Powles et al.
EUROPEAN UROLOGY (2011)
Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib
Brian I. Rini et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)
Efficacy of Sunitinib Re-Exposure after Failure of an mTOR Inhibitor in Patients with Metastatic RCC
Viktor Gruenwald et al.
ONKOLOGIE (2011)
Feasibility and efficacy of neoadjuvant sunitinib before nephron-sparing surgery
Jonathan L. Silberstein et al.
BJU INTERNATIONAL (2010)
Sunitinib Rechallenge in Metastatic Renal Cell Carcinoma Patients
Ivan N. Zama et al.
CANCER (2010)
Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis
Brett E. Houk et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2010)
A Decrease of Regulatory T Cells Correlates With Overall Survival After Sunitinib-based Antiangiogenic Therapy in Metastatic Renal Cancer Patients
Olivier Adotevi et al.
JOURNAL OF IMMUNOTHERAPY (2010)
Prospective Clinical Trial of Preoperative Sunitinib in Patients With Renal Cell Carcinoma
Nicholas J. Hellenthal et al.
JOURNAL OF UROLOGY (2010)
Reversible Epithelial to Mesenchymal Transition and Acquired Resistance to Sunitinib in Patients with Renal Cell Carcinoma: Evidence from a Xenograft Study
Hans J. Hammers et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Complexity of Tumor Vasculature in Clear Cell Renal Cell Carcinoma
Chao-Nan Qian et al.
CANCER (2009)
Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis
Marta Paez-Ribes et al.
CANCER CELL (2009)
Sunitinib Inhibition of Stat3 Induces Renal Cell Carcinoma Tumor Cell Apoptosis and Reduces Immunosuppressive Cells
Hong Xin et al.
CANCER RESEARCH (2009)
A Phase I Study of Sunitinib plus Bevacizumab in Advanced Solid Tumors
Brian I. Rini et al.
CLINICAL CANCER RESEARCH (2009)
Phase I Study Combining Treatment with Temsirolimus and Sunitinib Malate in Patients with Advanced Renal Cell Carcinoma
Premal H. Patel et al.
CLINICAL GENITOURINARY CANCER (2009)
Salvage Therapy with Bevacizumab-Sunitinib Combination after Failure of Sunitinib Alone for Metastatic Renal Cell Carcinoma: A Case Series
Jacques Medioni et al.
EUROPEAN UROLOGY (2009)
Phase I Trial of Bevacizumab Plus Escalated Doses of Sunitinib in Patients With Metastatic Renal Cell Carcinoma
Darren R. Feldman et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase II Study of Sunitinib Administered in a Continuous Once-Daily Dosing Regimen in Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma
Bernard Escudier et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
Robert J. Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial
Martin E. Gore et al.
LANCET ONCOLOGY (2009)
Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): A literature review
Kiran Gupta et al.
CANCER TREATMENT REVIEWS (2008)
Tumor escape from endogenous, extracellular matrix-associated angiogenesis inhibitors by up-regulation of multiple proangiogenic factors
Namali T. Fernando et al.
CLINICAL CANCER RESEARCH (2008)
Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: Results from a phase III randomized trial
David Cella et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma
Brian I. Rini et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period
Carolyn D. Britten et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2008)
Modes of resistance to anti-angiogenic therapy
Gabriele Bergers et al.
NATURE REVIEWS CANCER (2008)
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with anti-angiogenic and antitumour activities
J. G. Christensen
ANNALS OF ONCOLOGY (2007)
Sunitinib: From rational design to clinical efficacy
Laura Q. M. Chow et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: Current status and future directions
Alessandro Morabito et al.
ONCOLOGIST (2006)
Sunitinib in patients with metastatic renal cell carcinoma
Robert J. Motzer et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma
RJ Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer
S Faivre et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease
W Fiedler et al.
BLOOD (2005)
Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: A phase III, double-blind, randomized trial - The zoledronic acid lung cancer and other solid tumors study group
LS Rosen et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1α expression in renal cell carcinomas
X Na et al.
JOURNAL OF UROLOGY (2003)
Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma
RJ Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Share Paper
